NEW YORK – A SNP in a genomic region used to target SARS viruses can potentially impact non-diagnostic results from some commercial molecular diagnostic tests for COVID-19 infection. The issue highlights the need for multi-target tests and raises concerns about the industry practice of keeping primer and probe chemistries under wraps.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.